The CTD² Network and Cancer Systems Biology Consortium organized a virtual symposium series titled “Multidisciplinary Approaches to Understand Cancer Treatment Resistance”. Registration will open in mid-October for all symposium dates; please join us on 11/16, 11/17, 12/2, 12/16, and 12/17. Click here to view the draft agenda.
Publications
572 Publications Available
August 20, 2020
Nat Immunol.
August 01, 2020
Nat Protoc.
July 27, 2020
Nucleic Acids Res.
July 01, 2020
Mol Syst Biol.
June 30, 2020
Biochem Soc Trans.
June 11, 2020
Blood
Study highlights the usage of FDA-approved tyrosine kinase inhibitors for treating leukemia patients with neurotrophic receptor tyrosine kinase mutations.
June 01, 2020
Nature Chemical Biology
Integrated analysis of RNA-sequencing, proteomics, and phosphoproteomics data indicate doublecortin like kinase 1 (DCLK1) modulates proteins and pathways associated with cell motility in patient-derived pancreatic ductal adenocarcinoma (PDAC) organoids.
May 12, 2020
Nat Commun.
UCSF CTD2 scientists developed a multi-faceted testing framework and demonstrate that analysis of protein networks rather than a single gene identifies synthetic lethal candidates. These candidates are reproducible as they are dependent on genetic and cellular context.
Pages
.